ORAMED PHARMACEUTICALS INC. Tax Withholding Paid on Stock Awards
ORAMED PHARMACEUTICALS INC. (ORMP) reported Tax Withholding Paid on Stock Awards of $1.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-10
- ORAMED PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $352.00K.
- ORAMED PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $1.52M.
- ORAMED PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2022-12-31 was $0.00.
- ORAMED PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2022-09-30 was $106.00K.
- ORAMED PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $2.00K.
- ORAMED PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $783.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $352.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.87M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $1.52M 10-Q · filed 2026-05-19 | ||||
| 2026-03-30 | $1.52M 10-Q · filed 2026-08-10 | ||||
| 2026-03-26 | $121.00K 10-Q · filed 2026-08-10 | ||||
| 2024-12-31 | $2.00K 10-K · filed 2026-03-26 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $106.00K derived: sum of 2 quarters · filed 2024-03-06 | $106.00K derived: sum of 3 quarters · filed 2024-03-06 | $783.00K 10-K · filed 2024-03-06 | |
| 2022-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $106.00K derived: sum of 2 quarters · filed 2023-11-09 | $783.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $677.00K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $677.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |